George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 413.50
Bid: 414.00
Ask: 418.00
Change: 6.00 (1.47%)
Spread: 4.00 (0.966%)
Open: 411.00
High: 419.00
Low: 411.00
Prev. Close: 407.50
BNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Preferred Tier 1 Securities CoCos

7 May 2021 07:00

RNS Number : 8505X
Banco Santander S.A.
07 May 2021
 

 

 

 

 

Banco Santander, S.A. (Banco Santander" or the "Bank"), in compliance with the Securities Market legislation, hereby announces:

 

OTHER RELEVANT INFORMATION

 

 

Banco Santander announces that it has completed the placement of preferred securities contingently convertible into newly issued ordinary shares of the Bank, excluding pre-emptive subscription rights of its shareholders and for an aggregate nominal amount of EUR 1,583,333,333.33. The issue is divided into two series (i) one series in U.S. dollars (the "Dollars Series") and (ii) one series in euros (the "Euro Series"), the aggregate nominal amount of the Dollar Series being USD 1,000,000,000 (equivalent to c. EUR 833,333,333.33 at the euro/U.S. dollar exchange rate on 5 May 2021) and of the Euro Series EUR 750,000,000 (the "Issue" and the "CoCos").

 

The placement of the Issue has been carried out through an accelerated bookbuilding targeted at professional investors and eligible counterparties only.

 

The CoCos are issued at par and its remuneration, the payment of which is subject to certain conditions and to the discretion of the Bank, has been set (i) for the Dollars Series at 4.750% on an annual basis for the first six years, thereafter it will be reviewed every five years by applying a margin of 375.3 basis points on the 5-year UST and (ii) for the Euro Series at 4.125% on an annual basis for the first seven years, thereafter it will be reviewed every five years by applying a margin of 431.1 basis points on the rate resulting from the 5-year mid-swap applicable.

 

Once issued, the CoCos will be eligible as additional tier 1 capital of the Bank under the European Regulation 575/2013. The CoCos are perpetual, but they may be called under certain circumstances and would be converted into newly issued ordinary shares of Banco Santander if the common equity tier 1 (CET1) ratio of the Bank or its consolidated group, calculated in accordance with European Regulation 575/2013, were to fall below 5.125%. As of 31 March 2021, the consolidated CET1 ratio of the Bank was 12.30%.

 

The Bank will request the admission of the CoCos to trade on the New York Stock Exchange.

 

The Bank also announces that, as of today, the relevant reports of the directors of the Bank and the independent expert, both issued in accordance with articles 414.2, 417.2 and 510 of the Spanish Companies Act (Ley de Sociedades de Capital), will be available on the Bank's website (www.santander.com). The reports will also be provided to the shareholders at the first general shareholders' meeting to be held after the Issue.

 

 

 

Boadilla del Monte (Madrid), 6 May 2021

 

IMPORTANT INFORMATION

 

This communication of relevant information is not a prospectus and is not an offer or a solicitation to buy, sell, subscribe or exchange any securities issued or to be issued by the Bank. This document may not be distributed, directly or indirectly, in any jurisdiction in which said distribution is contrary to applicable laws.

 

No action has been made or will be taken that would permit a public offering of any securities described herein in any jurisdiction in which action for that purpose is required. No offers, sales, resales or delivery of any securities described herein or distribution of any offering material relating to any such securities may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Bank or the underwriters of the Issue or any of their respective affiliates. Additionally, the CoCos will not be offered, distributed or sold in Spain nor to Spanish residents.

 

This document is not an offer for sale of securities in the United States and the CoCos may not be offered or sold in the United States nor to, on behalf or for the benefit of, any citizen of the United States, as defined in the Regulation S of the US Securities Act of 1933, as amended ("US Securities Act"), unless such offer is registered or is exempt from the registration requirements under the US Securities Act.

 

In connection with the offering of the CoCos, the Bank has filed a registration statement (including a prospectus), and a prospectus supplement with the US Securities and Exchange Commission (the "SEC"). Before you invest, you should read the prospectus and prospectus supplement included in that registration statement and the other documents the Bank has filed with the SEC for more complete information about the Bank and the offer of the CoCos. You may obtain these documents for free by visiting the SEC web site at www.sec.gov.

 

This communication of relevant information is an announcement and not a prospectus and investors should not subscribe for or purchase any securities referred herein except on the basis of the information contained in the prospectus, the prospectus supplement and the other documents filed by the Bank with the SEC that are incorporated by reference in the registration statement.

 

This communication of relevant information does not constitute an offer document or an offer of transferable securities to the public in the United Kingdom to which section 85 of the Financial Services and Markets Act 2000 ("FSMA") applies and should not be considered as a recommendation that any person should subscribe for or purchase any of the securities described herein. These securities will not be offered or sold to any person in the United Kingdom except in circumstances which have not resulted and will not result in an offer to the public in the United Kingdom in contravention of section 85(1) of FSMA.

 

This communication of relevant information does not constitute an offer to the public in Italy of financial products, as defined under article 1, paragraph 1, letter (t) of legislative decree no. 58 of 24 February 1998, as amended (the "Financial Services Act"). The preferred securities cannot be offered or sold in the Republic of Italy to any natural persons nor to entities other than qualified investors (investitori qualificati) as defined pursuant to Article 100 of the Financial Services Act and Article 34-ter, paragraph 1, letter b) of Regulation No. 11971 of May 14, 1999, as amended (the "Issuers Regulations") issued by the Commissione Nazionale per le Società e la Borsa, the Italian securities and financial markets regulator ("CONSOB") or unless in circumstances which are exempt from the rules on public offers pursuant to Article 100 of the Financial Services Act and the implementing CONSOB regulations, including the Issuers Regulations. This communication of relevant information is for informational purposes only and does not constitute and shall not, in any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market.

 

Restrictions on Marketing and Sales to Retail Investors

 

The CoCos are not intended to be sold and should not be sold to retail clients (as defined in Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on Markets in Financial Instruments and amending Directive 2002/92/EC and Directive 2011/61/EU ("MiFID II"), as amended or replaced from time to time) and Regulation (EU) 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act of 2018 ("EUWA"). Prospective investors are referred to the section headed "Important Information" of the preliminary prospectus supplement for further information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDKABBBBKBBPK
Date   Source Headline
26th Apr 202411:28 amRNSBuyback programme: transactions 18-25 Apr
23rd Apr 202411:03 amRNSNotice of First Quarter 2024 Results
18th Apr 202411:04 amRNSBuyback programme: transactions 11-17 Apr
11th Apr 202411:07 amRNSBuyback programme: transactions 3-10 Apr
3rd Apr 202411:10 amRNSBuyback programme: transactions 21Mar-2Apr
2nd Apr 20245:07 pmRNSTotal Voting Rights
22nd Mar 20242:27 pmRNS2024 AGM - Resolutions
22nd Mar 20247:00 amRNSSantander is on its track to meet its 2024 targets
21st Mar 202410:52 amRNSBuyback programme: transactions 14-20 Mar
19th Mar 20249:47 amRNS2023 UK Annual Report
18th Mar 20245:46 pmRNSDirector/PDMR Shareholding
18th Mar 20245:37 pmRNSDirector/PDMR Shareholding
18th Mar 20245:26 pmRNSDirector/PDMR Shareholding
14th Mar 202411:04 amRNSBuyback programme: transactions 7-13 Mar
12th Mar 20249:30 amRNSForm 8.3 - Spirent Communications plc
7th Mar 202411:05 amRNSBuyback programme: transactions 29 Feb-6 Mar
29th Feb 20242:50 pmRNSTotal Voting Rights
29th Feb 202411:07 amRNSBuyback programme: transactions 20-28 Feb
27th Feb 20245:15 pmRNSDirector/PDMR Shareholding
27th Feb 20245:13 pmRNSDirector/PDMR Shareholding
27th Feb 20245:12 pmRNSDirector/PDMR Shareholding
21st Feb 20243:33 pmRNSDirector/PDMR Shareholding
20th Feb 20247:00 amRNSNotice of AGM
19th Feb 202411:17 amRNSDividend approval & buyback program implementation
19th Feb 20247:45 amRNSFurther re dividend approval
19th Feb 20247:43 amRNSDividend approval & buyback program implementation
7th Feb 20244:39 pmRNSDirector/PDMR Shareholding
7th Feb 20244:38 pmRNSDirector/PDMR Shareholding
7th Feb 20244:36 pmRNSDirector/PDMR Shareholding
5th Feb 20245:48 pmRNSFurther re capital reduction
1st Feb 20244:46 pmRNSDirector/PDMR Shareholding
31st Jan 20243:55 pmRNSTotal Voting Rights
31st Jan 20247:00 amRNS2023 Results - Press release
31st Jan 20247:00 amRNS2023 Results Report & Earnings Presentation
26th Jan 202411:32 amRNSCapital reduction following completion of program
26th Jan 202411:19 amRNSTransaction in Own Shares
24th Jan 202411:06 amRNSNotice of 2023 Results Presentation
18th Jan 202411:05 amRNSBuyback programme: transactions 11-17 Jan
11th Jan 202411:08 amRNSBuyback programme: transactions 4-10 Jan
4th Jan 202411:07 amRNSBuyback programme: transactions 28 Dec- 3 Jan
29th Dec 202311:58 amRNSTotal Voting Rights
28th Dec 202311:08 amRNSBuyback programme: transactions 21-27 Dec
21st Dec 202311:07 amRNSBuyback programme: transactions 14-20 Dec
20th Dec 20234:14 pmRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSAdapting reporting to new operating model (ppt)
20th Dec 20237:00 amRNSAdapting reporting to new operating model (PR)
18th Dec 20235:22 pmRNSDirector/PDMR Shareholding
18th Dec 20235:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:05 amRNSDirector/PDMR Shareholding
14th Dec 202311:05 amRNSBuyback programme: transactions 5-13 Dec

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.